S. Lusvarghi

This study compares how N-glycan modifications affect spike expression, infectivity, and antibody neutralization in SARS-CoV-2 D614G and Omicron variants.

The paper compares antibody responses to different SARS-CoV-2 variants after vaccination and infection, finding that post-vaccination Omicron infection induces broader immunity than triple vaccination alone.

This study characterizes the entry mechanisms and antibody neutralization resistance of Omicron variants BA.1, BA.1.1, BA.2, and BA.3 compared to the D614G strain.

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

This study evaluates the neutralization resistance and spike protein properties of SARS-CoV-2 B.1.617 variants, finding modest resistance to sera and therapeutic antibodies, but enhanced cleavage and fusogenic activity in Delta variants.

The paper evaluates resistance of 25 therapeutic antibodies to SARS-CoV-2 variants with multiple spike substitutions, finding key substitutions predict resistance but other substitutions can modify it unpredictably.

This study characterizes zebrafish homologs of the human ABCB1 gene, showing that abcb4 closely resembles P-gp in function and localization, while abcb5 differs.

This paper describes ensovibep, a trispecific DARPin that inhibits SARS-CoV-2 variants by targeting the spike protein, showing potent antiviral activity and protection in animal models.

This paper identifies 90 P-gp substrates from 10,804 compounds using a high-throughput screen, including 55 new substrates confirmed by orthogonal assays.